magnesium-orotate and Arrhythmias--Cardiac

magnesium-orotate has been researched along with Arrhythmias--Cardiac* in 2 studies

Reviews

1 review(s) available for magnesium-orotate and Arrhythmias--Cardiac

ArticleYear
Magnesium orotate--experimental and clinical evidence.
    Romanian journal of internal medicine = Revue roumaine de medecine interne, 2004, Volume: 42, Issue:3

    Magnesium orotate dihydrate (MO) has the sum formula C10H6MgN4O8 x 2H2O and a MG of 370.52. The salt is poorly soluble in water and hence does not bind gastric acid nor does it exhibit noteworthy laxative effects upon oral administration in contrast to easily dissociable Mg salts. As a source of magnesium (Mg), MO is indicated for the oral treatment of extracellular Mg deficiency. Orotic acid (OA), the second active ingredient of MO, is a key intermediate in the biosynthetic pathway of pyrimidines and is shown to improve the energy status of injured myocardium by stimulating, a.o., the synthesis of glycogen and ATP. Myocardial energy-rich phosphate levels are decreased during hypoxic conditions; subsequently, intracellular Mg is depleted and lost via the urine. Since binding sites for Mg (ATP) are provided by OA it can be classified as "Mg-fixing agent". Accordingly MO is also indicated for the treatment of Mg depletion as convincingly shown in animal experiments and also in coronary heart patients undergoing e.g. aortocoronary bypass surgery.

    Topics: Angina Pectoris; Animals; Arrhythmias, Cardiac; Biological Availability; Clinical Trials as Topic; Heart; Heart Diseases; Heart Failure; Humans; Hyperlipidemias; Hypertension; Magnesium Deficiency; Orotic Acid

2004

Trials

1 trial(s) available for magnesium-orotate and Arrhythmias--Cardiac

ArticleYear
[Adrenoreactivity in patients with arrhythmic syndrome associated with connective tissue dysplasia at the background of intake of the magnezium orotate].
    Kardiologiia, 2011, Volume: 51, Issue:3

    Elevated level of -adrenoreception of membranes is observed in patients with disturbances of heart rhythm at the background of connective tissue dysplasia. It is not related to characteristics of the arrhythmic syndrome. At the background of 4-months intake of preparation magnezium orotate significant decrease of degree of desensitization of of erythrocytes has been noted.

    Topics: Adult; Arrhythmias, Cardiac; Cardiotonic Agents; Catecholamines; Connective Tissue Diseases; Erythrocyte Membrane; Female; Humans; Male; Orotic Acid; Receptors, Adrenergic, beta; Sympathetic Nervous System; Treatment Outcome

2011